Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Requip XL User Fee Date Pushed Back To Second Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA needs additional time to review food effect data from GlaxoSmithKline for the once-daily Parkinson's treatment.

You may also be interested in...



FDA Clears GSK’s Requip XL For Parkinson’s

Once-daily version is designed to battle generic competitors.

FDA Clears GSK’s Requip XL For Parkinson’s

Once-daily version is designed to battle generic competitors.

Generic Requip Cleared For RLS

Teva, Mylan, Roxane and Par will market ropinirole for Restless Legs Syndrome; Parkinson's patent expires this month, too.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel